Company news

Tenax Therapeutics, Inc. news in 2026

Tenax Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Tenax Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

November 5, 2026

Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

September 1, 2026

Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026

August 29, 2026

Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF

August 10, 2026

Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

July 31, 2026

Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026

July 1, 2026

Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 12, 2026

Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 8, 2026

Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer

May 4, 2026

Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer

April 22, 2026

Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

March 9, 2026

Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference

March 3, 2026

Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026

February 4, 2026

Decks in 2026